Aerovate Therapeutics Inc
NASDAQ:AVTE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.41
30.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Aerovate Therapeutics Inc
Aerovate Therapeutics Inc
Cash from Investing Activities
Aerovate Therapeutics Inc
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
Cash from Investing Activities
$11.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$19.7B
|
CAGR 3-Years
-121%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$4B
|
CAGR 3-Years
31%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-13%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$27.7B
|
CAGR 3-Years
-304%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$2.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-17%
|
|
Aerovate Therapeutics Inc
Glance View
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The firm's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The firm has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. The company anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.
See Also
What is Aerovate Therapeutics Inc's Cash from Investing Activities?
Cash from Investing Activities
11.9m
USD
Based on the financial report for Dec 31, 2023, Aerovate Therapeutics Inc's Cash from Investing Activities amounts to 11.9m USD.
What is Aerovate Therapeutics Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 1Y
71%
Over the last year, the Cash from Investing Activities growth was 71%.
You don't have any saved screeners yet
